SpineThera

Our drug doubles the clinical efficacy rate of injections for low back pain. $2B revenue potential for lead drug . Platform tech with multiple opportunities.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Minneapolis, MN, USA
  • Currency USD
  • Founded September 2012
  • Employees 6
  • Incorporation Type C-corp
  • Website spinethera.com

Company Summary

Back pain is the leading cause of disability, the most expensive condition to treat, and closely linked to the opioid crisis. We have developed a best-in-class injectable drug that doubles the efficacy rate and extends the duration of therapeutic benefit by 6X compared to current standard of care. With proof-of-concept clinical results in hand, we are seeking investment partners to move our lead asset to Phase 3 readiness and through Phase 3.

Team

  • Jeff Missling
    CEO

    20 years in development of long-acting injectable drugs
    $30M capital raised in career
    2 prior out-licensing deals in long-acting injectables
    Formerly at SurModics, St. Jude Medical, 3M

  • Lee Techner
    Chief Medical Officer

    15 years of clinical practice with a large orthopedic surgery center.
    Over 20 years of drug development as a Medical Director at a global CRO, Omnicare. Medical lead at Adolor for alvimopan. VP Clinical Research and Cubist for Entereg., 10 years of consulting as CMO on multiple pain drug development programs with numerous drug development programs moving through FDA Division of Anesthesia, Addiction Medicine and Pain Medicine (DAAP).

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free